{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:12:53Z","timestamp":1793394773349,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.anai.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T19:38:42Z","timestamp":1596915522000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Group 2 innate lymphoid cells in nasal polyposis"],"prefix":"10.1016","volume":"126","author":[{"given":"Whitney W.","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl S29","key":"10.1016\/j.anai.2020.08.001_bib1","first-page":"1","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2020.08.001_bib2","first-page":"S22","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"9","key":"10.1016\/j.anai.2020.08.001_bib3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.alit.2014.12.006","article-title":"Immunopathology of chronic rhinosinusitis","volume":"64","author":"Kato","year":"2015","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cea.12472","article-title":"Pathogenesis of nasal polyposis","volume":"45","author":"Hulse","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.anai.2020.08.001_bib6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.anai.2020.08.001_bib7","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2020.08.001_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2020.01.013","article-title":"Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis","volume":"124","author":"Staudacher","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.chest.2019.04.101","article-title":"Group 2 innate lymphoid cells in airway diseases","volume":"156","author":"Kato","year":"2019","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.anai.2020.08.001_bib12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.anai.2020.08.001_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ni.2104","article-title":"Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161","volume":"12","author":"Mjosberg","year":"2011","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.anai.2020.08.001_bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41590-018-0201-4","article-title":"Tissue signals imprint ILC2 identity with anticipatory function","volume":"19","author":"Ricardo-Gonzalez","year":"2018","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaci.2020.01.038","article-title":"Optimal identification of human conventional and nonconventional (CRTH2-IL7\u03b1-) ILC2s using additional surface markers","volume":"146","author":"Liu","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1164\/rccm.201212-2227OC","article-title":"IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps","volume":"188","author":"Shaw","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clim.2014.09.007","article-title":"Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness","volume":"155","author":"Walford","year":"2014","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2020.08.001_bib18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/all.12440","article-title":"Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis","volume":"69","author":"Miljkovic","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2020.08.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2016.07.010","article-title":"Group 2 innate lymphoid cells are increased in nasal polyps in patients with eosinophilic chronic rhinosinusitis","volume":"170","author":"Tojima","year":"2016","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/iid3.161","article-title":"Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps","volume":"5","author":"Poposki","year":"2017","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbrc.2015.06.005","article-title":"ICOS promotes group 2 innate lymphoid cell activation in lungs","volume":"463","author":"Kamachi","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.imlet.2007.07.002","article-title":"Intracellular JNK, p38 MAPK and NF-kappaB regulate IL-25 induced release of cytokines and chemokines from costimulated T helper lymphocytes","volume":"112","author":"Wong","year":"2007","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.anai.2020.08.001_bib23","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1111\/all.13552","article-title":"Epithelial activators of type 2 inflammation: elevation of thymic stromal lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois","volume":"73","author":"Ogasawara","year":"2018","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaci.2018.03.019","article-title":"Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps","volume":"142","author":"Kohanski","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2020.08.001_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.08.001_bib26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ni.3447","article-title":"IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity","volume":"17","author":"Ohne","year":"2016","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.immuni.2016.11.005","article-title":"Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency","volume":"46","author":"Simoni","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5114\/ada.2017.67842","article-title":"Differential expression of tumor necrosis factor \u03b1, interleukin 1\u03b2, nuclear factor \u03baB in nasal mucosa among chronic rhinosinusitis patients with and without polyps","volume":"34","author":"Plewka","year":"2017","journal-title":"Postepy Dermatol Alergol"},{"issue":"9","key":"10.1016\/j.anai.2020.08.001_bib29","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1002\/lary.27112","article-title":"Olfactory and middle meatal cytokine levels correlate with olfactory function in chronic rhinosinusitis","volume":"128","author":"Wu","year":"2018","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000341668","article-title":"Characterization of IL-18 expression and release in the pathogenesis of chronic rhinosinusitis","volume":"160","author":"Okano","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.08.001_bib31","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s10753-016-0442-z","article-title":"Role of NLRP3 inflammasome in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps","volume":"39","author":"Lin","year":"2016","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jaci.2013.04.005","article-title":"Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis","volume":"132","author":"Nagarkar","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.001_bib33","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaci.2016.08.040","article-title":"Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans","volume":"139","author":"Poposki","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jaci.2019.09.001","article-title":"TNF induces production of type 2 cytokines in human group 2 innate lymphoid cells","volume":"145","author":"Ogasawara","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41385-019-0215-8","article-title":"Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps","volume":"13","author":"Ogasawara","year":"2020","journal-title":"Mucosal Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/mi.2013.92","article-title":"TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers","volume":"7","author":"Yu","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.001_bib37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jaci.2018.01.028","article-title":"GITR cosignal in ILC2s controls allergic lung inflammation","volume":"141","author":"Nagashima","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaci.2013.03.048","article-title":"Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production","volume":"132","author":"Doherty","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib39","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaci.2016.12.958","article-title":"Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines","volume":"140","author":"Salimi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib40","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jaci.2013.10.056","article-title":"Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells","volume":"133","author":"Xue","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.08.001_bib41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaci.2005.02.029","article-title":"Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis","volume":"115","author":"Perez-Novo","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2332\/allergolint.O-08-545","article-title":"Correlation between the prostaglandin D(2)\/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma","volume":"57","author":"Yoshimura","year":"2008","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2012.08.015","article-title":"The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells","volume":"37","author":"Mjosberg","year":"2012","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2017.09.025","article-title":"IL-10, TGF-\u03b2, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells","volume":"141","author":"Ogasawara","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.001_bib46","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5 Pt 1","key":"10.1016\/j.anai.2020.08.001_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects","volume":"143","author":"Christie","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2011.01.065","article-title":"Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma","volume":"128","author":"Roca-Ferrer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.001_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2016.11.023","article-title":"Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease","volume":"140","author":"Eastman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2020.08.001_bib51","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.001_bib52","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.08.001_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2332\/allergolint.11-RA-0403","article-title":"Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites","volume":"61","author":"Higashi","year":"2012","journal-title":"Allergol Int"},{"issue":"6","key":"10.1016\/j.anai.2020.08.001_bib54","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.jaci.2018.10.069","article-title":"Cytokine-induced endogenous production of prostaglandin D2 is essential for human group 2 innate lymphoid cell activation","volume":"143","author":"Maric","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.001_bib55","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jaci.2017.09.050","article-title":"Prostaglandin E2 suppresses human group 2 innate lymphoid cell function","volume":"141","author":"Maric","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10209","key":"10.1016\/j.anai.2020.08.001_bib56","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.anai.2020.08.001_bib57","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cea.13514","article-title":"Blockade of IL-4R\u03b1 inhibits group 2 innate lymphoid cell responses in asthma patients","volume":"50","author":"Patel","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"10.1016\/j.anai.2020.08.001_bib59","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/eji.201948161","article-title":"Th2 cell-derived IL-4\/IL-13 promote ILC2 accumulation in the lung by ILC2-intrinsic STAT6 signaling in mice","volume":"49","author":"Symowski","year":"2019","journal-title":"Eur J Immunol"},{"issue":"515","key":"10.1016\/j.anai.2020.08.001_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.anai.2020.08.001_bib61","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2020.08.001_bib62","doi-asserted-by":"crossref","first-page":"1700670","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2020.08.001_bib63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/PPA.S46192","article-title":"A\u00a0review of denosumab for the treatment of osteoporosis","volume":"8","author":"Miyazaki","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"10.1016\/j.anai.2020.08.001_bib64","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1365-2222.2010.03630.x","article-title":"Leukotriene modifiers for asthma treatment","volume":"40","author":"Montuschi","year":"2010","journal-title":"Clin Exp Allergy"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620305573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620305573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:25:23Z","timestamp":1761053123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120620305573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1081120620305573"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.08.001","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Group 2 innate lymphoid cells in nasal polyposis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}